From Treating Cancer to Curing Cancer – The Promise of mRNA Vaccines in Oncology

ASCO 2022: Striving to Ensure No Patient is Left Behind

Opportunities and Challenges for Drug Makers in MDD

Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases

Building and Defending Markets; Reflections on Attending DTx and NASS Conferences

Resurgence in Drug Development for Renal Diseases

AI in Healthcare: Insights from Two Decades of FDA Approvals

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

India, the Generic Manufacturing Powerhouse, Biosimilar Next?

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

When Off-Label is Your Biggest Competition: Rituximab in Autoimmune Diseases

Hong Kong Exchange: Nurturing China’s Biotech Valley

Biopharma R&D in the Post-COVID World

eBook: Biopharma in the COVID-19 World

Against All Odds: Can Covid-19 Usher in a New Era in International Public Health Cooperation?

Is Cardiovascular R&D Ready for a Comeback?

SARS-CoV-2 Landscape of Repurposed Drug Trials and Key Lessons for the Future

COVID-19 Impact on Rare Disease Patients and Manufacturers

Protective Antibody Therapy: Preventing Future COVID-19 Outbreaks

Launch Costs—Spend Wisely: Analysis by Order of Entry

Health Advances Blog

Category: BioPharma

From Treating Cancer to Curing Cancer – The Promise of mRNA Vaccines in Oncology

ASCO 2022: Striving to Ensure No Patient is Left Behind

Opportunities and Challenges for Drug Makers in MDD

Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases

Building and Defending Markets; Reflections on Attending DTx and NASS Conferences

Resurgence in Drug Development for Renal Diseases

AI in Healthcare: Insights from Two Decades of FDA Approvals

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

India, the Generic Manufacturing Powerhouse, Biosimilar Next?

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

When Off-Label is Your Biggest Competition: Rituximab in Autoimmune Diseases

Hong Kong Exchange: Nurturing China’s Biotech Valley

Biopharma R&D in the Post-COVID World

eBook: Biopharma in the COVID-19 World

Against All Odds: Can Covid-19 Usher in a New Era in International Public Health Cooperation?

Is Cardiovascular R&D Ready for a Comeback?

SARS-CoV-2 Landscape of Repurposed Drug Trials and Key Lessons for the Future

COVID-19 Impact on Rare Disease Patients and Manufacturers

Protective Antibody Therapy: Preventing Future COVID-19 Outbreaks

Launch Costs—Spend Wisely: Analysis by Order of Entry